View Older Stories
-
Intercept to Present at Upcoming Conference
-
Intercept Pharma (ICPT) Price Target $160 Maintained at BMO Capital
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $160 at BMO Capital After FDA Outlines Ocaliva SAE
-
Intercept Pharma (ICPT): Management Meetings Soothe Investor Fears Ahead Of Catalyst - BMO
-
Buy Weakness in Intercept Pharmaceuticals (ICPT) - BMO
-
Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital on 2Q Report; 'Solid 2Q17 Earnings + Two Positive Phase 2 Readouts... Buy on Weakness'
-
Pre-Open Stock Movers 07/31: (DVAX) (CHTR) (DAN) Higher; (HTZ) (CLVS) (ICPT) Lower (more...)
-
Intercept Pharmaceuticals (ICPT) PT Raised to $223 at BMO Capital; 'Ocaliva Off to a Strong Start'
-
Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital
-
Intercept Pharmaceuticals (ICPT) NASH Trial Changes Increase Probability of Success and Timely Approval - BMO
-
Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN
-
Intercept (ICPT) OCA Off to Gradual Start in PBC, BMO Capital Notes; PT to $218
-
Intercept (ICP) OCA Approval a 'Major De-Risking Event' - BMO
-
Streetinsider.com's Hot Lunchtime Reads 5/3: (AAPL) (ICPT) (VRX) (TSLA)
-
Intercept Pharmaceuticals (ICPT) Settlement Removes Minor Overhang - BMO Capital
-
Notable Analyst Rating Changes 4/7: (MTH) (GT) (CBRL) Upgraded; (VZ) (HOG) (FFIV) Downgraded
-
After-Hours Stock Movers 04/06: (OLLI) (APOG) (VRX) Higher; (RPTP) (ALDR) (EBAY) Lower (more...)
-
BMO Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform
-
Notable Analyst Rating Changes 4/5: (CHMT) (SXL) (ICPT) Upgraded; (LPLA) (LYB) (HRL) Downgraded
-
BMO Capital Says Buy Intercept Pharmaceuticals (ICPT) on Weakness Related to Trial Design
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital Amid Data
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital as Competitor Data in PBC Support Role of OCA
-
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
-
Intercept Pharma (ICPT) 1M Stock Offering Prices at $176/Share
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital amid American Journal of Pathology OCA Data
-
Genfit Data Not Seen as Competitive Threat to Intercept Pharmaceuticals (ICPT) - BMO Capital
-
Notable Analyst Rating Changes 12/4: (INFI) (MBLY) (CSX) Upgraded; (DISH) (RIO) (WMT) Downgraded
-
BMO Capital Retains Bullish Stance on Intercept Pharmaceuticals (ICPT) Following Q3 Results, FLINT Data
-
Balanced Intercept (ICPT) FLINT Review Will Leave Near-Term Debate, BMO Capital Says
-
BMO Capital Affirms Intercept (ICPT) at 'Outperform'; FLINT Data Won't be Presented at AASLD
-
Notable Analyst Rating Changes 08/12: (ANF) (ICUI) (DF) Upgraded; (AMCC) (WHX) (TCK) Downgraded
-
Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at BMO Capital Following FLINT Data
-
Galectin (GALT) Disappointment Positive for Intercept Pharmaceuticals (ICPT) - BMO Capital
-
Intercept Pharma (ICPT) Higher after 2-Day Slide
-
Amid E-Mails and Phone Records, BMO Capital Believes Intercept (ICPT) FLINT Trial Was Stopped Early For Efficacy
-
Notable Analyst Rating Changes 05/15: (PLUG) (PTX) (TWTR) Upgraded; (BMY) (HII) (CXP) Downgraded
-
Intercept Pharma (ICPT) Prices 1M Common Offering at $320/Share
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Intercept Pharma (ICPT) to Offer 1M Shares
-
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 04/01: (ICPT) (ISRG) (MSFT) (DDD)
-
Intercept (ICPT) Competitive Risk from Galectin (GALT) 'Deminimus' - BMO Capital
-
Stocks Weaker, Led by High-Beta Names
-
Intercept (ICPT) Positive POISE Trial Helps Balance FLINT CV Risk, BMO Capital Says
-
Intercept Pharmaceuticals (ICPT) Price Target Raised to $515 at BMO
-
Intercept Pharmaceuticals (ICPT) Target Raised to $270 at BMO Capital
-
Intercept Pharma (ICPT) Prices 1.73M Common Offering at $33.01/Share
-
BMO Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform
-
Intercept Pharmaceuticals (ICPT) IPO Trades 26% Higher